PHARMACY

Medco announces scholarship program for pharmacy students

BY Diana Alickaj

FRANKLIN LAKES, N.J. Medco Labor Coalition has announced that it will be offering a scholarship program to students, in support of their efforts in achieving a degree in pharmacy.

The scholarship is based on a student’s academic achievement, his or her commitment to a career in pharmacy, leadership and community service, according to published reports. Medco is the nation’s leading pharmacy benefit manager, and the only coalition focused on providing pharmacy benefits to small and medium-sized unions.

National reports estimate that there will be a shortage of about 157,000 pharmacists needed to fill prescriptions for millions of patients in the U.S. The ever-increasing role of the pharmacist has elevated the status of the line of work to areas of engineering, genetics, manufacturing, drug development, public policy and clinical specialization. By promoting this new scholarship program, it will enhance the drive for students to be involved in these areas of pharmacy.

“A career in pharmacy is now so much more than it was just a few years ago, literally transcending plastic trays and counting pills to now encompassing everything from genetics and personalized medicine to electronic prescribing,” Pamela Miller, vice president of market strategy and development for Medco stated. “Delivering prescription care in the 21st century presents one of the greatest domestic healthcare challenges to our nation, and we’re excited to support students today who hold the promise for tomorrow.”

The deadline for applications is April 15, 2008 and can be mailed to:Medco Labor Coalition Scholarship, 4320-G Wade Hampton Blvd.,Taylors, SC  29687or online at <a title="www.scholarshipprograms.org” href=”http://www.scholarshipprograms.org/” target=”_blank” />www.scholarshipprograms.org.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Cornelius elected to chairman of Bristol-Myers Squibb board

BY Adam Kraemer

NEW YORK Bristol-Myers Squibb Wednesday announced that the company’s board of directors has elected chief executive officer James Cornelius as chairman of the board. He will continue serving in his previous role as well.

The board also named Textron’s chairman, president and chief executive officer Lewis Campbell, chairman, president as lead independent director. James Robinson III, co-founder and general partner of RRE Ventures, resigned as non- executive chairman of the Board, a position he has held since June 2005. He will remain a director of the company until May 6, 2008, the date of the company’s annual meeting of stockholders, when he will retire pursuant to the Board’s mandatory age retirement policy.

Cornelius was named chief executive officer of Bristol-Myers Squibb on April 30, 2007, after serving as interim chief executive officer since September 12, 2006. He joined the Board in January 2005. “I am excited by this tremendous opportunity to serve as chairman of the Board of this great company,” he stated. “Over the past 18 months as chief executive officer, I have been deeply impressed by the commitment and dedication of our employees to our mission and goals, and the strong belief they share with me in the promise of Bristol-Myers Squibb as a BioPharma leader for the future.”

Cornelius was previously a member of the board of directors of Eli Lilly, a member of its executive committee and chief financial officer from 1983 to 1995.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Duragesic pain patches getting recall

BY Adam Kraemer

WASHINGTON Ortho-McNeil-Janssen, a unit of drug and consumer giant Johnson & Johnson on Tuesday said it was recalling certain strengths of its Duragesic pain patches, which have the potential to expose patients to a dangerous gel inside.

All lots of Ortho-McNeil’s 25 microgram-per-hour strength patch of Duragesic are being recalled, in coordination with the Food and Drug Administration.

The recalled patches may have an opening which could result in release of the gel—made of the drug fentanyl—inside, Reuters reported. Exposure to fentanyl directly can cause serious harm, including breathing problems and overdose, which can be fatal, the company said.

All the recalled patches have an expiration date on or before December 2009.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?